SciCombinator

Discover the most talked about and latest scientific content & concepts.

S O'Brien, RR Furman, SE Coutre, JP Sharman, JA Burger, KA Blum, B Grant, DA Richards, M Coleman, WG Wierda, JA Jones, W Zhao, NA Heerema, AJ Johnson, R Izumi, A Hamdy, BY Chang, T Graef, F Clow, JJ Buggy, DF James and JC Byrd
Abstract
Chemoimmunotherapy has led to improved numbers of patients achieving disease response, and longer overall survival in young patients with chronic lymphocytic leukaemia; however, its application in elderly patients has been restricted by substantial myelosuppression and infection. We aimed to assess safety and activity of ibrutinib, an orally administered covalent inhibitor of Bruton tyrosine kinase (BTK), in treatment-naive patients aged 65 years and older with chronic lymphocytic leukaemia.
Tweets*
28
Facebook likes*
2
Reddit*
0
News coverage*
1
Blogs*
0
SC clicks
0
Concepts
B-cell chronic lymphocytic leukemia, Protein kinase, Small lymphocytic lymphoma, Hematology, Cancer, Leukemia
MeSH headings
-
comments powered by Disqus

* Data courtesy of Altmetric.com